
Chemours rated 'BUY' with $20 target, poised for recovery by 2027-28 amid debt reduction and EBITDA growth.
Chemours (CC) is rated as a 'BUY' with a price target of $20 and a fair value of $30, indicating it is currently undervalued with strong recovery potential. The investment thesis focuses on the company's operating leverage, efforts to repair its bala...





